Your trusted source for investing success

Tag: cancer cells

Looking for Cannabis Stocks?

Read our report to find market data, important news and stocks to watch!

VBL Therapeutics Presents Late Breaking Research Demonstrating Immune-cell Mediated Killing of Cancer Cells by a Novel Bi-specific Antibody at AACR

VBL Therapeutics (NASDAQ:VBLT) today presented a late-breaking study demonstrating a novel bi-specific antibody that induces immune-cell mediated killing of cancer cells through binding to a tumor membrane receptor, MOSPD2. Data are presented today at the American Association for Cancer Research (AACR) 2018 Annual Meeting in Chicago, Illinois.

As quoted in the press

Endocyte Presents Data from its CAR T Platform at American Association for Cancer Research (AACR) Annual Meeting 2018

Endocyte (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced in a late-breaking poster session the presentation of new research from Endocyte’s chimeric antigen receptor T-cell (CAR T) adaptor molecule (CAM) platform at the AACR Annual Meeting 2018 in Chicago, IL.

As quoted in the press release:

Telix Pharmaceuticals, INSERM and ARRONAX Enter into Translational Research Partnership

Telix Pharmaceuticals (ASX:TLX) a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has today announced a research partnership with the French National Institute of Health and Medical Research (Institut national de la santé et de la recherche médicale or

Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with CellBridge

Precision Therapeutics (NASDAQ:AIPT) formerly Skyline Medical, announced today that its wholly owned subsidiary, TumorGenesis has secured a license agreement with CellBridge Incorporated which grants it access to CellBridge’s 3D biomimetic support technology. This follows the Company’s recently announced license agreements with SyntArray and 48Hour Discovery and is the latest milestone in the Company’s strategy to

Biotech Stocks in 2018

Find out how the market will look this year

Enter Your Log In Credentials
This setting should only be used on your home or work computer.


Privacy & Legal Policy

Privacy Policy

Investing News Network

Send this to a friend

I thought you might find this interesting:
Cannabis Weekly Round-Up: New Merger in the Public Markets